Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore the top credit cards that provide the most rewards. Maximize your benefits and make the most of your spending.
25,405 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A detailed look at Seer’s Q1 2026 earnings, the forces shaping growth, and practical moves investors can make now. Le...
Amcor trades around $39 with a 5.8% forward yield, presenting a potential income safe-haven under $40 as market volat...
As mortgage rates stay elevated and dividend yields fluctuate, many savers question whether rental cash flow or divid...
The AI memory boom has traders watching the Roundhill Memory ETF. With a potential SK Hynix ADR list around July 10, ...
Meta signals a bold move into AI compute power and model access. The shift could redefine cloud dynamics, affect riva...
Lynx Investment Advisory recently disclosed a meaningful stake in the Akre Focus ETF, signaling confidence in a quali...
In uncertain times, one reliable approach is to target recession-resistant dividend stocks. This article shines a lig...
A closer look at how Lawrence Calcano built iCapital into a leading wealth-tech platform for alternatives. Learn the ...
A fresh take on LUCD's early 2026 results, this analysis dives into the lucd 2026 earnings transcript to unpack reven...
A small, obscure quantum-focused ETF has vaulted in 2026, delivering outsized gains versus the S&P 500 and NASDAQ as ...
AI shares pulled back in a volatile session as rate worries resurfaced. Analysts say Nvidia stock remains a key barom...